MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clcc.2026.02.003

Медицинская библиотека · Clinical colorectal cancer · 2026

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.

Bocobo Andrea, Whitman Julia, Keenan Bridget P, Koser Kelvin L, Kidder Wesley A, Piawah Sorbarikor, Van Loon Katherine, Behr Spencer C, Kolli K Pallav, Chen Xiaoying, Onodera Courtney, Pande Manjusha, Pollak Marin, Wang Renee, Babdor Joel, Spitzer Matthew H, Zhang Li, Fong Lawrence, Atreya Chloe E

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

This study evaluated the safety, tolerability and preliminary efficacy of pembrolizumab in combination with capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

PATIENTS AND

METHODS

Patients with MSS/pMMR mCRC with stable or progressive disease on at least 1 prior fluoropyrimidine-based therapy received capecitabine 1000 mg/m2 by mouth twice daily days 1 to 14, bevacizumab 7.5 mg/kg day 1, and pembrolizumab 200 mg day 1 every 3 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were safety, duration of response, progression-free survival (PFS), and overall survival (OS).

RESULTS

Forty-four patients were enrolled between April 2018 and October 2021. Median follow up time was 9.3 months, while median time on treatment was 6 months. Overall response rate for 40 evaluable patients was 5% with median duration of response of 13.5 months. Median PFS was 4.1 months, and median OS was 10.1 months. Grade ≥ 3 treatment related adverse events occurred in 13 patients (30%); none were classified as immune-related. Grade 1 to 2 immune-related adverse events occurred in 8 patients (18%). Dose modifications occurred in 27 patients (61%), most commonly for palmar-plantar erythrodysesthesia. Single cell RNA sequencing on a subset of tumor biopsies demonstrated that the frequency of dendritic cells and tumor-infiltrating activated T cells correlated with time on treatment.

CONCLUSIONS

The combination of pembrolizumab with capecitabine and bevacizumab was tolerable with an expected toxicity profile in MSS/pMMR mCRC patients. The overall response rate of 5% did not meet the prespecified target of ≥ 15%; however, 55% patients remained on treatment > 6 months.

CLINICALTRIALS: gov Identifier: clinicaltrials.gov: NCT03396926.

Для цитирования: Bocobo Andrea, Whitman Julia, Keenan Bridget P, Koser Kelvin L, Kidder Wesley A, Piawah Sorbarikor, Van Loon Katherine, Behr Spencer C, Kolli K Pallav, Chen Xiaoying, Onodera Courtney, Pande Manjusha, Pollak Marin, Wang Renee, Babdor Joel, Spitzer Matthew H, Zhang Li, Fong Lawrence, Atreya Chloe E. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.. Clinical colorectal cancer. 2026. DOI: 10.1016/j.clcc.2026.02.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.